Scarica l'app Stockscreener
34.14
5.11%
1.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$32.48
Aprire:
$33.58
Volume 24 ore:
3.49M
Relative Volume:
1.66
Capitalizzazione di mercato:
$3.51B
Reddito:
$164.01M
Utile/perdita netta:
$-65.04M
Rapporto P/E:
-49.69
EPS:
-0.687
Flusso di cassa netto:
$-383.84M
1 W Prestazione:
+16.08%
1M Prestazione:
+27.34%
6M Prestazione:
+30.45%
1 anno Prestazione:
+100.94%
Intervallo 1D:
$32.66
$34.35
Intervallo di 1 settimana:
$28.67
$34.35
Portata 52W:
$15.60
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
34.14 | 3.51B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - Zacks Investment Research
Beam Therapeutics stock soars 21% in three months: Here's why - MSN
Beam Therapeutics (BEAM) Receives FDA Approval for BEAM-304 IND Application - GuruFocus
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial - Stock Titan
Beam Therapeutics gets FDA clearance for BEAM-304 - grafa.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial - Investing.com
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beam Therapeutics Inc (BEAM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beam Therapeutics Inc (BEAM) Institutional Confidence - TradingKey
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why - The Globe and Mail
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts? - Yahoo Finance
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
BEAM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Precision Trading with Beam Therapeutics Inc. (BEAM) Risk Zones - Stock Traders Daily
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Amova Asset Management Americas Inc. Cuts Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Geode Capital Management LLC Sells 39,035 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (Nasdaq: BEAM) shareholders approve directors, auditor and pay - Stock Titan
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Beam Therapeutics (BEAM) director receives 19,676-share option grant - Stock Titan
Beam Therapeutics (BEAM) director receives stock options grant for 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) grants 19,676 stock options to director - Stock Titan
Beam Therapeutics (BEAM) director receives stock options on 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) awards stock options to director Chirfi - Stock Titan
Beam Therapeutics (BEAM) awards director Graham Cooper 19,676 options - Stock Titan
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 10.1% HigherWhat's Next? - MarketBeat
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
BEAM Technical Analysis & Stock Price Forecast - Intellectia AI
Beam Therapeutics Stock Hits Day Low of $28.80 Amid Price Pressure - Markets Mojo
Beam Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Technical Reactions to BEAM Trends in Macro Strategies - Stock Traders Daily
Draft FDA guidance could be a boon for gene therapy developers - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - AOL.com
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD - Yahoo Finance
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):